Industry has been quick to embrace decentralized trials as a lasting change, de-risked by the pandemic, and are reporting positive effects and cost savings. But during a recent panel at the Galien Foundation Forum, an important voice – former and possibly future US Food and Drug Administration commissioner Robert Califf – urged some caution about moving too fast.
During a 28 October panel discussion on how decentralized clinical trials (DCTs) are modernizing clinical research, industry experts reflected on the changes that have taken place to accommodate these new...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?